GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

GeneDx Holdings Corp. (NASDAQ: WGS) is facing a securities class action lawsuit due to alleged misrepresentations regarding its acquisition performance and a subsequent 49% stock decline. Investors who purchased shares between April 16, 2025, and May 4, 2026, have until August 3, 2026, to file lead plaintiff applications. The lawsuit claims GeneDx and its executives failed to disclose material information. On May 4, 2026, the company reported a drop in adjusted gross margin, missed revenue estimates for its exome and genome lines, and lowered its full-year revenue guidance. Additionally, a $31.2 million impairment loss related to the acquisition of Fabric Genomics was disclosed, leading to a 49.2% drop in GeneDx's stock price.